Guitton et al[6] (2018), in a multi-center retrospective cohort study including 18 patients with SLE-ITP treated with TPO-R agonists, 55% (10 patients) had APLA and 27% (5 patients) had definite APS. This evidence concerns the gene MPL and systemic lupus erythematosus.